Cellect Biotechnology   Report issue

For profit Phase 2
Founded: Kfar Saba Israel (2011)

Organization Overview

First Clinical Trial
2017
NCT02828878
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Cellect Biotechnology

Active Ingredients

Drugs in Phase 2 Trials (1)

allogeneic adipose derived mesenchymal stem cell (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Graft vs Host Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1